NUCANA PLC-ADR
NCNANASDAQTrading Snapshot
- Day Range
- $1.19 – $1.22
- 52-Week Range
- —
- Volume
- $3.00B
- Avg Volume
- $2.24B
- Shares Outstanding
- 20.81B
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.47B
- Last Q Revenue
- $676M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- +14602.6%
Why Investors Own NCNA
- ✓High-growth profile — revenue up +56.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NUCANA PLC-ADR
NCNA
StockOtter · stockotter.spaceAbout NUCANA PLC-ADR
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
